L'intérêt à découvert pour Eli Lilly donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Eli Lilly. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Eli Lilly (NYSE:LLY) Stock, Rapport sur les intérêts à découvert

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

On Wednesday, Verge Genomics announced that Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis (ALS) as part of the companies&#8217; collaboration, which was <a target="_blank" href="https://www.benzinga.com/general/biotech/21/07/21892739/eli-lilly-verge-genomics-ink-720m-pact-for-amyotrophic-lateral-sclerosis-therapies" rel="noreferrer noopener">initiated in July 2021</a>.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig&#8217;s disease, is a nervous system disease that affects the nerve cells in the brain and spinal cord.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42070751/eli-lillys-investigational-drug-cuts-sticky-cholesterol-levels-by-almost-86" rel="noreferrer noopener">Eli Lilly&#8217;s Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%</a>
Verge&#8217;s AI-enabled CONVERGE&nbsp;platform identified and validated the targets, with 83% of prioritized targets validated in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42082756/verge-genomics-announces-milestones-in-collaboration-with-lilly-to-discover-and-develop-novel-trea" rel="noreferrer noopener">disease-relevant models</a>.
Target selection triggered near-term milestone payments from Lilly to Verge. As the programs progress, Verge is eligible for additional downstream economics.
In 2021, Verge and Lilly entered a three-year collaboration to discover and validate novel therapeutic targets for ALS that would become the focus for subsequent drug discovery and development.
Verge received up to $25 million in upfront equity investment and potential near-term milestones, with a total deal value of $694 million plus potential downstream royalties.
Verge also continues to advance VRG50635, its internal lead drug candidate for sporadic and familial ALS.
VRG50635 is currently being evaluated in a Phase 1B Proof-of-Concept (PoC) study in Canada and several European countries. Enrollment is complete and dose escalation, including to the highest dose level, is ongoing.
Price Action: Eli Lilly stock is up 2.75% at about $749 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42093116/global-e-surges-as-gmv-and-revenue-outperform-expectations-in-q3" target="_blank" rel="noreferrer noopener">Global-E Soars: Q3 Sales Surge 32%, FY24 Outlook Raised Amid GMV Boom</a></li>
</ul>

Biotech

Large Cap

News

Health Care

Contracts

General

Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate

The Federal Trade Commission (FTC) is facing legal challenges from three competing pharmacy-benefit managers (PBMs) over its attempt to restrict their ability to negotiate drug prices for <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41256923/cvs-unitedhealth-request-ftc-chair-recusal-amid-ongoing-pharmacy-benefit-managers-lawsuit" rel="noreferrer noopener">health plan sponsors</a>.
In September, the FTC filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark,&nbsp;Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), Express Scripts, and&nbsp;UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">price of insulin medications</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The&nbsp;complaint&nbsp;accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">prescriptions in the U.S</a>.
The PBMs argue that this action seeks to upend current drug rebate contracts and disrupt long-standing practices, all while expanding the FTC&#8217;s authority beyond traditional limits.
The companies also <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/ExpressScriptsIncetalvFederalTradeCommissionetalDocketNo424cv0154?doc_id=X11H3MUIQJ4995RQ9NSUPGSE2AP" rel="noreferrer noopener">contend</a> that the administrative proceeding violates constitutional principles by lacking independent judicial oversight and claim that the FTC&#8217;s approach could result in significant and irreparable injury.
The lawsuit stems from the FTC&#8217;s attempt to regulate the drug rebate system, allowing PBMs to secure manufacturers&#8217; discounts.
However, the FTC&#8217;s complaint accuses the PBMs of using their power to create an unfair market, alleging that the system allows drug manufacturers to inflate prices.
In challenging the FTC&#8217;s action, the PBMs argue that this is not just a market dispute but a constitutional issue.
They assert that the FTC&#8217;s administrative proceeding, taking place in an in-house forum where the agency decides the facts, the law, and the outcome, is unconstitutional.
Furthermore, the PBMs argue that the FTC&#8217;s decision to handle the case through this in-house process, with a partisan panel of Democratic commissioners, deprives them of a fair trial.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42094248/trumps-return-boosts-palantir-national-security-bets-drive-140-billion-market-cap" target="_blank" rel="noreferrer noopener">Palantir Tech&#8217;s $140 Billion Market Cap Gain Is Driven By Trump&#8217;s Victory And Higher Defense Spending Hope &#8211; Is The Stock Overvalued?</a></li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Government

Regulations

Legal

Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System

WIIM

Eli Lilly shares are trading higher after Verge Genomics announced a collaboration with the company to discover and develop novel treatments for ALS.

— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics' AI-Enabled, All-in-Human CONVERGE Platform
— Demonstration of the Robust Predictive Power of CONVERGE&#xAE; - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards

Verge Genomics Announced Milestones In Collaboration With Lilly To Discover And Develop Novel Treatments For ALS; Lilly To Develop Two Targets Identified By Verge Genomics

In 2025, Walker will collaborate with Lilly on certain digital commercial activities.
Moeller is the chairman of the board, president and chief executive officer of Procter &amp; Gamble (P&amp;G).&nbsp;

Management

Eli Lilly Elects Jon Moeller As New Member Of Its Board, Effective Dec. 1, 2024; Karen Walker To Transition Her Role, Resigning As Member Of Board, Effective Dec. 31, 2024

Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when <a href="https://www.benzinga.com/quote/LLY/news">it tumbled 20.2%. </a>
The pharmaceutical giant, which ranks 11th by market capitalization in the S&amp;P 500 and holds the top spot among health care stocks, is reeling from a disappointing third-quarter earnings report and lowered guidance.
The sell-off raised doubts about the near-term prospects for Lilly's high-profile drugs Mounjaro and Zepbound, which missed revenue expectations and contributed to a storm of investor uncertainty.
For traders, the burning question now is whether Eli Lilly's pullback represents an opportunity to "buy the dip" in a high-quality, highly profitable company that maintains a position of dominance in the health care market.
<h1 class="wp-block-heading">Chart: LLY Shares On Track For Worst Month In Over 15 Years</h1>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-1024x501.png" alt="" class="wp-image-655565" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h1 class="wp-block-heading">The Catalyst: Weak Third-Quarter Earnings and Downgraded Guidance</h1>
Eli Lilly's third-quarter earnings report, released on Oct. 30, triggered the stock's steep decline in November.
While the company has been riding high on the success of its diabetes and obesity drugs, Mounjaro and Zepbound, both underperformed this quarter, missing revenue expectations by 14% and 26%, respectively.
Alec W. Stranahan, an analyst at Bank of America, said, "The focus this quarter was again on Mounjaro and Zepbound, which missed revenue expectations by a wide margin."
In response to the weak performance, Eli Lilly adjusted its full-year revenue guidance. 
The company lowered the high end of its forecast, projecting $45.4 billion to $46 billion, down from the previous range of $45.4 billion to $46.6 billion.
Lilly management attributed the third-quarter shortfall to temporary "inventory dynamics" rather than a fundamental decline in demand, reassuring investors that this was not indicative of a broader problem with its flagship drugs.
The company also highlighted its ongoing direct-to-consumer (DTC) promotional efforts, which began in the third quarter and are expected to drive sales growth in the fourth quarter and into 2025.
Despite the negative quarter, Bank of America remains bullish on Eli Lilly despite the recent stumble. Stranahan reaffirmed his "Buy" rating on the stock with a 12-month price target of $1,100, implying a 55% upside from current levels.
Instead, Goldman Sachs took a more cautious stance, maintaining a "Neutral" rating on Eli Lilly with a 12-month price target of $890, implying a 24% upside from current levels.
Chris Shibutani, M.D., described the third quarter as a "challenging update" and flagged the $1 billion shortfall in tirzepatide revenues as a significant concern. 
He expressed skepticism about whether the company can achieve its revised fourth quarter and 2025 revenue guidance.
The analyst urges caution ahead, highlighting that Eli Lilly's guidance assumes significant execution on multiple fronts, from inventory management to international expansion. "These factors need to cooperate for LLY to deliver," Shibutani said.
<h1 class="wp-block-heading">How Did Eli Lilly Shares React After Double-Digit Monthly Sell-offs?</h1>
Double-digit monthly selloffs have been a rarity for Eli Lilly, with only four occurrences in the past 15 years where the stock dropped more than 10% in a single month.
Interestingly, past data shows Eli Lilly has historically rebounded strongly following such declines.
Here's how the stock performed one month and three months after these major sell-offs:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Month</th>
<th>LLY Monthly Loss (%)</th>
<th>LLY 1-Month Forward (%)</th>
<th>LLY 3-Month Forward (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 2020</td>
<td>-11.9%</td>
<td>+11.6%</td>
<td>+59.5%</td>
</tr>
<tr>
<td>September 2021</td>
<td>-10.6%</td>
<td>+10.2%</td>
<td>+19.8%</td>
</tr>
<tr>
<td>January 2022</td>
<td>-11.2%</td>
<td>+14.6%</td>
<td>+28.4%</td>
</tr>
<tr>
<td>July 2024</td>
<td>-11.2%</td>
<td>+24.1%</td>
<td>+2.3%</td>
</tr>
</tbody>
</table>
</figure>
While history doesn't guarantee future results, the data suggests that Eli Lilly shares have demonstrated resilience following steep sell-offs, with gains ranging from 10.2% to 24.1% one month later and a solid average of positive returns over three months.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42041147/novo-nordisk-to-offer-wegovy-in-china-at-fraction-of-usa-cost">Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?

On Monday,&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;announced Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a genetically inherited risk <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42047055/lillys-muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-" rel="noreferrer noopener">factor for heart disease</a>.
In the U.S., about 20% of people, or approximately 63 million individuals, have high levels of Lp(a).
Elevated Lp(a) levels can double or even triple the risk of a heart attack and are associated with other cardiovascular issues.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/42039286/eli-lillys-zepbound-mounjaro-shows-cardiovascular-benefits-in-patients-with-obesity-related-heart-failure" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure</a>
The study demonstrated that muvalaplin significantly reduced elevated Lp(a) levels in adults, meeting its primary endpoint.
At the 12-week primary endpoint, muvalaplin (10 mg, 60 mg, and 240 mg) significantly reduced Lp(a) levels compared to placebo.
The placebo-adjusted reductions were up to 85.8% using an intact Lp(a) assay and up to 70.0% using an apo(a) assay.
<ul>
<li>Specifically, the reductions were 47.6% (10 mg), 81.7% (60 mg) and 85.8% (240 mg) with the intact Lp(a) assay, and 40.4% (10 mg), 70.0% (60 mg) and 68.9% (240 mg) with the apo(a) assay.</li>
</ul>
Muvalaplin also met secondary endpoints for all three tested doses (10 mg, 60 mg, and 240 mg).
<ul>
<li>The three tested doses achieved statistical significance for Lp(a) thresholds, and the 60 mg and 240 mg doses also achieved statistical significance for apoB reductions.</li>
</ul>
These data also demonstrated:
<ul>
<li>Using the intact Lp(a) assay, the percentage of participants achieving normal Lp(a) levels of less than 125 nmol/L at week 12 was 64.2% (10 mg), 95.9% (60 mg), and 96.7% (240 mg), compared to 6.0% in the placebo group.</li>
<li>Using the apo(a) assay, 38.9% (10 mg), 81.9% (60 mg), and 77.4% (240 mg) of participants achieved an Lp (a) level of less than 125 nmol/L, compared to 3.6% in the placebo group.</li>
<li>ApoB levels were reduced at all doses, with placebo-adjusted reductions of 8.9% (10 mg), 13.1% (60 mg) and 16.1% (240 mg).</li>
</ul>
Adverse events were similar in both the muvalaplin and placebo groups.
Price Action: LLY stock is down 0.44% at $723.97&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42060801/walmart-tops-q3-estimates-ecommerce-growth-shines-with-27-lifts-full-year-forecast" target="_blank" rel="noreferrer noopener">Walmart Q3 Earnings: Revenue Beat, eCommerce Growth Shines, Issues Bullish Outlook For FY25</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%

Eli Lilly Canada Inc. (Lilly Canada) is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final Recommendation for Ebglyss&#x2122;&nbsp;(lebrikizumab), published on Friday, November 15, 2024. The CDA-AMC recommended&nbsp;that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and adolescents 12 years of age and older.1
Lilly Canada stands behind Ebglyss as a first-line biological therapy for the treatment of atopic dermatitis and we remain committed to patients. Access to Ebglyss for new and existing patients with moderate-to-severe AD via LillyPlus&#xAE;&nbsp;will not change as we tenaciously pursue options for private and public reimbursement in Canada. We have shared our concerns with the CDA-AMC leadership and believe that the CDA-AMC are applying differential standards to biologic therapies for the treatment of AD that are not founded upon their own requirements. Lilly Canada continues to explore all options to overcome this recommendation.

Global

Eli Lilly Canada Is Disappointed And Strongly Disagrees With Canada's Drug Agency's Final Recommendation For Ebglyss, Published On Friday, November 15, 2024; CDA-AMC Recommended That Ebglyss Not Be Reimbursed By Public Drug Plans, Excluding Quebec, For Moderate-To-Severe Atopic Dermatitis

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is a buy. &#8220;This stock is as hated now as it was loved not that <a href="https://www.benzinga.com/markets/equities/24/11/42039286/eli-lillys-zepbound-mounjaro-shows-cardiovascular-benefits-in-patients-with-obesity-related-heart-failure">long ago,&#8221; he added</a>.
Eli Lilly on Monday said Muvalaplin met secondary endpoints for <a href="https://www.benzinga.com/pressreleases/24/11/n42047055/lillys-muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-">all three tested doses.</a>
Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) is a &#8220;winner,&#8221; Cramer said.
On Monday, Needham analyst John Todaro maintained Coinbase with a Buy and raised the price target from $290 to $375.
Cramer said IES Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) is a &#8220;terrific&#8221; infrastructure play.
IES Holdings will release fiscal 2024 fourth quarter and year-end results before the opening bell on Friday, Nov. 22.
&#8220;I do think that Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is just a traditional kind of semiconductor company,&#8221; Cramer said. He added that he prefers Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) to that one.
Semtech will release the financial results of its third quarter of fiscal year 2025 after the closing bell on Monday, Nov. 25.
&#8220;It is an incredibly expensive stock versus the rest of the market,&#8221; Cramer said when asked about Cameco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>). &#8220;I am a ‘ka-ching ka-ching' when it comes to Cameco.&#8221;
On Nov. 7, Cameco raised its FY24 revenue guidance.
The &#8220;Mad Money&#8221; host said he likes Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>).
Marvell Technology will release its third-quarter fiscal year 2025 financial results on Tuesday, Dec. 3, followed by a conference call to discuss the results.
Cramer said own Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and not trade it. &#8220;I would wait for a dip because the bears are all over it every minute of the day. Keep that in mind, and then pull the trigger,&#8221; he added.
A consumer group called &#8220;Which?&#8221; recently filed a £3 billion ($3.81 billion) legal claim against Apple, accusing the tech giant of breaching UK competition law <a href="https://www.benzinga.com/news/global/24/11/41964915/apple-faces-legal-action-over-rip-off-icloud-charges-could-pay-out-38b-to-uk-customers">through its iCloud service</a>.
Price Action:
<ul>
<li>Eli Lilly shares fell 2.6% to settle at $727.20 on Monday.</li>
<li>Apple shares gained 1.3% to close at $228.02.</li>
<li>Coinbase shares gained 6.4% to close at $325.41.</li>
<li>IES shares climbed 2.6% to settle at $264.67 during the session.</li>
<li>Semtech shares gained 3.9% to close at $45.84 on Monday.</li>
<li>Cameco shares gained 4.3% to settle at $55.90 during the session.</li>
<li>Marvell shares gained 1% to close at $88.71 on Monday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

AAPL

COIN

IESC

MRVL

SMTC

Jim Cramer: Coinbase Is A 'Winner,' Suggests Buying This 'Hated' Big Pharma Stock

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 41 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 26% bearish. Among these notable options, 27 are puts, totaling $1,787,322, and 14 are calls, amounting to $807,770.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $520.0 to $950.0 for Eli Lilly over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 358.06 with a total volume of 1,100.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $520.0 to $950.0 over the last 30 days.
<h3>Eli Lilly Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732031174_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$57.7</td>
<td>$52.75</td>
<td>$55.5</td>
<td>$650.00</td>
<td>$416.2K</td>
<td align="right">153</td>
<td align="right">77</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$44.15</td>
<td>$41.2</td>
<td>$43.0</td>
<td>$850.00</td>
<td>$129.0K</td>
<td align="right">0</td>
<td align="right">20</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$59.5</td>
<td>$57.1</td>
<td>$57.1</td>
<td>$720.00</td>
<td>$119.9K</td>
<td align="right">211</td>
<td align="right">23</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$233.5</td>
<td>$226.4</td>
<td>$229.83</td>
<td>$950.00</td>
<td>$114.9K</td>
<td align="right">66</td>
<td align="right">0</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$71.85</td>
<td>$70.2</td>
<td>$70.2</td>
<td>$750.00</td>
<td>$112.3K</td>
<td align="right">200</td>
<td align="right">19</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,880,416, the price of LLY is down by -0.65%, reaching $722.49.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>What The Experts Say On Eli Lilly</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1068.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Eli Lilly, targeting a price of $975. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1100. 
&#x2A; An analyst from Wolfe Research has revised its rating downward to Outperform, adjusting the price target to $1000. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1250. 
&#x2A; An analyst from Deutsche Bank has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1015. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Eli Lilly Unusual Options Activity

Eli Lilly Says Muvalaplin Met Secondary Endpoints For All Three Tested Doses

Lilly's Muvalaplin Reduces Lipoprotein(a) Levels By Up To 85% In High-Risk Cardiovascular Patients In Phase 2 Study; Results Published In JAMA And Presented At AHA 2024 Scientific Sessions

On Saturday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) released detailed results from the SUMMIT Phase 3 trial showing tirzepatide reduced the risk of worsening heart failure events in adults with heart failure with preserved ejection fraction <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42024061/lillys-tirzepatide-reduced-the-risk-of-worsening-heart-failure-events-by-38-in-adults-with-heart-f" rel="noreferrer noopener">(HFpEF) and obesity</a>.
The 731-patient SUMMIT study showed that patients treated with tirzepatide also experienced improvements in heart failure symptoms and physical limitations.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for-even-at-three-years" rel="noreferrer noopener">99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly&#8217;s Detailed Phase 3 Data Shows</a>
The FDA approved tirzepatide as Mounjaro for adults with type 2 diabetes to improve glycemic control in May 2022 and Zepbound for adults with obesity or those who are overweight who also have at least one weight-related medical problem in November 2023.
The results from the SUMMIT trial of tirzepatide in obese patients with heart failure with preserved ejection fraction (HFpEF) showed that Lilly&#8217;s drug cut the risk of cardiovascular mortality and worsening heart failure events by 38% over a median follow-up of roughly two years.
After a median follow-up of two years and a maximum of three years, cardiovascular death or worsening heart failure events occurred in 9.9% of the tirzepatide group and 15.3% of those taking a placebo.
Assessing individual endpoints, worsening heart-failure events occurred in 8% of tirzepatide participants and 14.2% of placebo participants, for an HR of 0.54 (95% CI, 0.34-0.85), whereas adjudicated cardiovascular deaths occurred in 2.2% and 1.4% of tirzepatide and placebo participants, respectively.
The risk of hospitalization for heart failure was reduced by 56%.
In addition, patients taking tirzepatide saw a nearly 25-point improvement in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), which measures symptoms and physical limitations associated with heart failure, compared to a 15-point improvement for the placebo group.
All key secondary endpoints were also met, with patients treated with tirzepatide demonstrating improved exercise capacity, walking approximately 30 meters farther in six minutes than those on placebo (38.2 meters vs. 7.9 meters).
Additionally, patients treated with tirzepatide saw an average reduction in body weight of 15.7%, compared to 2.2% in the placebo group.
Tirzepatide also significantly decreased high-sensitivity C-reactive protein, a key marker of systemic inflammation, by 43.4%, while the placebo group saw a 3.5% decrease.
Lilly said it has already started submitting the SUMMIT data to the FDA and European Medicines Agency regulators for HFpEF and obesity, seeking to extend the labeling for tirzepatide.
Price Action: LLY stock is down 2.54% at $727.27 at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42032495/alibaba-eyes-5-billion-bond-sale-to-fund-debt-payoff-and-stock-buybacks" target="_blank" rel="noreferrer noopener">Alibaba Eyes Raising $5 Billion Via Bond Sale to Fund Debt Payoff and Stock Buybacks</a></li>
</ul>

Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure

<ul>
<li>In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations</li>
<li>Patients on tirzepatide experienced improved exercise capacity, greater weight loss and reduced systemic inflammation</li>
<li>Lilly has initiated submissions for tirzepatide for the treatment of HFpEF and obesity to global regulatory agencies</li>
</ul>

Reported Saturday, Eli Lilly's Tirzepatide Cuts Heart Failure Risk By 38% In Adults With Heart Failure With Preserved Ejection Fraction (HFpEF) And Obesity

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 weight-loss drugs like Ozempic.
What Happened: Jan Hatzius, chief economist at Goldman Sachs, has said that US GDP could potentially grow an additional 1% if 60 million Americans were to use GLP-1 drugs by 2028.
Hatzius pointed out that health-related issues such as obesity often hinder people from participating in the labor force, thereby stunting economic growth, <a href="https://www.businessinsider.com/us-economy-faster-growth-ozempic-glp-1-weight-loss-drugs-2024-2">reports</a> Business Insider.
He further highlighted that healthcare innovation could significantly reduce the economic costs associated with poor health.
&#8220;Combining current losses in hours worked and labor force participation from sickness and disability, early deaths, and informal caregiving, we estimate that GDP would potentially be over 10% higher if poor health outcomes did not limit labor supply in the US,&#8221; the outlet quoted Hatzius saying.
GLP-1 drugs, including Ozempic and Mounjaro, are manufactured by Novo Nordisk and Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) respectively. These drugs have proven effective in treating type 2 diabetes and obesity, leading to a surge in sales.
Also Read: <a href="https://www.benzinga.com/markets/equities/24/07/39680165/eli-lillys-mounjaro-outpaces-novo-nordisks-ozempic-in-weight-loss-effectiveness-study-shows">Eli Lilly&#8217;s Mounjaro Outpaces Novo Nordisk&#8217;s Ozempic In Weight Loss Effectiveness, Study Shows</a>
Given the U.S. obesity rate of approximately 40%, tens of millions of Americans could be prescribed GLP-1 drugs in the upcoming years. Hatzius believes that this could lead to substantial economic benefits, including increased productivity.
&#8220;The main reason we see meaningful upside from healthcare innovation is that poor health imposes significant economic costs. There are several channels through which poor health weighs on economic activity that could diminish if health outcomes improve,&#8221; Hatzius said.
&#8220;These estimates therefore suggest that obesity-related health complications subtract over 3% from per-capita output, implying an over 1% hit to total output when combined with the over 40% incidence of obesity in the US population,&#8221; he added.
Why It Matters: The increased use of GLP-1 drugs could not only address the health crisis related to obesity but also stimulate economic growth. 
With the U.S. grappling with high obesity rates, the potential for these drugs to improve health outcomes and boost labor force participation could have far-reaching implications for the economy. 
The surge in sales of these drugs also indicates a growing market, which could further contribute to economic growth.
Read Next
<a href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th">As Race To Best &#8216;Miracle&#8217; Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%</a>
This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image: Shutterstock

Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/11/2024-11-15_08h38_46.png" alt="" style="width:624px" /></figure>
<h3 class="wp-block-heading">Powell Speaks The Truth</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-powell-speech-trump-appointments-spy-mc-11152024">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul>
<li>It is worth a reminder that The Arora Report is politically agnostic.&nbsp; Our sole job is to help our members extract the maximum amount of money out of the markets with the least possible risk.</li>
<li>The price action on the chart shows that the rip roaring Trump rally is taking a breather.</li>
<li>The chart shows that the stock market is still above the breakout line.</li>
<li>RSI on the chart shows that the stock market has pulled back, reflecting a loss of momentum. The stock market is still overbought.</li>
<li>The chart shows that the volume remains low.&nbsp; This indicates that institutional investors are not rushing to buy stocks.</li>
<li>Yesterday, Powell spoke that truth – the market did not like it.&nbsp; Powell said, "The economy is not sending any signals that we need to be in a hurry to lower rates."&nbsp; Powell elaborated, "The strength we are currently seeing in the economy gives us the ability to approach our decisions carefully."</li>
<li>Powell's remarks brought some selling into stocks and bonds.</li>
<li>This morning, in the early trade, selling continues.</li>
<li>The reason for some selling is that the prevailing wisdom on Wall Street has been that another rate cut in December was a sure thing.&nbsp; The Arora Report has been questioning Wall Street's wisdom and sharing with you that the data does not support another rate cut.</li>
<li>Some conservative commentators are upset believing that the reason Powell started rate cuts with a 50 bps cut was to help Kamala Harris get elected.&nbsp; Now that Trump has been elected, Powell is in no hurry to cut rates.</li>
<li>In The Arora Report analysis, even though the data does not support a rate cut in December, Powell is going to feel pressure from Trump and Republicans to cut rates.&nbsp; There is also a significant amount of data between now and the December Fed meeting.</li>
<li>In The Arora Report analysis, based on a 360 degree view, including the political pressure and the pressure from Wall Street to cut rates, the probability of a rate cut in December is now about 60%.&nbsp;&nbsp;</li>
<li>There is consternation about several Trump picks.&nbsp; Impacting the market most are Trump's picks of RKF Jr, Matt Gaetz, and Pete Hegseth.&nbsp; These picks are bringing selling in vaccine makers such as Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), BioNTech SE ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).&nbsp; There is also selling in other healthcare stocks, including weight loss drug companies Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and packaged food stocks such as The Kraft Heinz Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>).&nbsp; There is also selling in defense stocks such as Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), Northrop Grumman Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), and Rtx Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>).&nbsp; There is also selling in big tech stocks.</li>
<li>The latest economic data is strong.&nbsp; The U.S. economy is about 70% consumer based.&nbsp; For this reason, prudent investors pay attention to retail sales.&nbsp; Here are the details of the just released data:
<ul>
<li>Retail sales came at 0.4% vs. 0.3% consensus.</li>
<li>Retail sales ex-auto came at 0.1% vs. 0.2% consensus.</li>
</ul>
</li>
<li>There are hundreds of indicators.&nbsp; At The Arora Report, the system has been refined through decades of research to share with you only those indicators that matter.&nbsp; Normally, we do not mention the NY Fed Empire State Manufacturing Index.&nbsp; Today, we are mentioning it due to its exceptional strength.&nbsp; The index came at 31.2 vs. 3.3 consensus.&nbsp; This indicates that manufacturing in the New York area has picked up steam. &nbsp; If similar strength is happening in the rest of the country, that would argue against further cutting interest rates. The problem for investors is that stock valuations are so high that to sustain them, rate cuts are needed.&nbsp;&nbsp;</li>
</ul>
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are negative in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
In the early trade, money flows are negative in S&amp;P 500 ETF (SPY) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).  The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).  The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h3 class="wp-block-heading">Bitcoin</h3>
Even the slightest dips in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) are being bought.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Politics

Federal Reserve

$BTC

AMZN

BNTX

GOOG

MRNA

MSFT

NVAX

NVDA

TSLA

Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth

VRTX

Shares of pharmaceutical companies are trading lower After President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

Wolfe Research analyst Alexandria Hammond initiates coverage on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Outperform rating and announces Price Target of $1000.

Price Target

Initiation

Analyst Ratings

Wolfe Research Initiates Coverage On Eli Lilly with Outperform Rating, Announces Price Target of $1000

Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has filed a lawsuit against the Health Resources and Services Administration (HRSA). The pharmaceutical giant claims that HRSA obstructed its attempt to alter drug discount offerings to hospitals.
What Happened: As per Eli Lilly&#8217;s official statement on Thursday, the conflict centers on the federal 340B program, which requires drug manufacturers to offer discounts to healthcare providers serving low-income communities. Participation in this program is crucial for drug companies to secure funding from government health insurance programs like Medicare and Medicaid.
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis. However, HRSA, a division of the U.S. Health and Human Services Department, rejected this approach, stating it was inconsistent with the 340B law.
&#8220;HRSA does not have the authority to arbitrarily reject this model, which serves the original goals of the 340B program and improves transparency, efficiency, and program integrity,&#8221; the statement read.
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Why It Matters: The lawsuit comes amid ongoing scrutiny of drug pricing practices. Recently, <a href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price">Doctors Without Borders</a> criticized Eli Lilly and other insulin manufacturers for maintaining high prices, urging them to provide affordable insulin to low- and middle-income countries.
This legal action also <a href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs">follows a similar lawsuit</a> by Johnson &amp; Johnson, which alleged the Health and Human Services Department of blocking its drug rebate plans. The 340B program has been subject to extensive legal challenges, with a U.S. appeals court previously allowing drugmakers to limit the use of outside pharmacies for dispensing under the program.
Meanwhile, Eli Lilly has been in the spotlight for its <a href="https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for-even-at-three-years">Phase 3 trial data</a> of tirzepatide, marketed as Mounjaro and Zepbound. The study showed promising results in reducing the risk of type 2 diabetes in patients with pre-diabetes and obesity, highlighting the company&#8217;s focus on innovative treatments.
Price Action: Eli Lilly was down by 0.28% during pre-market hours on Friday at the time of writing, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41921267/new-jersey-is-making-history-by-offering-medical-cannabis-as-employee-benefit?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">New Jersey Is Making History By Offering Medical Cannabis</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program

<a href="https://x.com/DonaldJTrumpJr/status/1857168002837352564" title="https://x.com/DonaldJTrumpJr/status/1857168002837352564">https://x.com/DonaldJTrumpJr/status/1857168002837352564</a>

Donald Trump Jr. Posts On X "Robert F Kennedy Jr will be The Secretary of Health and Human Services! Promises Made Promises Kept"

Goldman's Hedge Fund VIP List: AMZN, VST, CRM, BABA, and more

Verge Genomics and Eli Lilly have made significant progress in their collaboration to develop ALS treatments, identifying two promising drug targets using AI technology.

LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs

Eli Lilly in pact with Chinese biotech for novel weight loss therapy

Earlier on Wednesday, Laekna, "a global biotech company focused on novel drug development for metabolic and cancer diseases," accoding to its relea...

Eli Lilly and China-based biotech Laekna team on obesity drug

Eli Lilly made a reversal bottom low on Monday after a gap lower. Today's price action was confirmation.

Are Diet Drug Companies Over The Hump?

Hershey: A Deep Dive Into A Confectionery Giant Facing Headwinds

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $1,000.00. ...

Eli Lilly & Co: Buy Rating Amid Valuation, Growth Prospects, and IPI Concerns

Franklin DynaTech Fund Q3 2024 Commentary

HQH: Declines Bring Potential Opportunity

Franklin Growth Opportunities Fund Q3 2024 Commentary

ALIT

ANSS

ASML

AVGO

AXON

AZNCF

BABA

BKNG

CORZ

CPNG

CRWD

CVNA

EXPE

FLUT

GILD

GOOGL

INSM

INTU

JNPR

KLAC

LBRDK

LRCX

MELI

MPWR

NFLX

NTRA

PINS

PYPL

REGN

SMAR

SPOT

TEVA

UBER

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-24 at 12.03.42 AM

ABBV

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Earnings

Press Releases

Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products

Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board

Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks

Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose

Lilly announces changes on board of directors

Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS

BioRestorative Ends Q3 In 'Strong' Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Comments

Eli Lilly

Intérêt court

Eli Lilly (NYSE:LLY) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL